About PAVmed
PAVmed is a company based in New York (United States) founded in 2014. PAVmed has raised $845 thousand across 13 funding rounds from investors including HHS. The company has 39 employees as of December 31, 2024. PAVmed offers products and services including Lucid Diagnostics and Veris Health. PAVmed operates in a competitive market with competitors including Medtronic, GE Healthcare, Boston Scientific, Guardant Health and Johnson & Johnson, among others.
- Headquarter New York, United States
- Employees 39 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pavmed Inc.
-
Annual Revenue
$3 M (USD)22.15as on Dec 31, 2024
-
Net Profit
$39.79 M (USD)0as on Dec 31, 2024
-
EBITDA
-$43.29 M (USD)34.27as on Dec 31, 2024
-
Total Equity Funding
$845 K (USD)
in 13 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Feb 03, 2026
- Investors
-
Employee Count
39
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of PAVmed
PAVmed is a publicly listed company on the NASDAQ with ticker symbol PAVM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of PAVmed
PAVmed offers a comprehensive portfolio of products and services, including Lucid Diagnostics and Veris Health.
Provides tests for detecting esophageal precancer.
Offers remote monitoring for personalized cancer care.
People of PAVmed
Unlock access to complete
Unlock access to complete
Funding Insights of PAVmed
PAVmed has successfully raised a total of $845K across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PAVmed
PAVmed has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for PAVmed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PAVmed
Investment portfolio details for PAVmed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PAVmed
Detailed financials for PAVmed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pavmed Comparisons
Peer comparison for PAVmed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PAVmed
PAVmed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Medtronic, GE Healthcare, Boston Scientific, Guardant Health and Johnson & Johnson, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Medical equipment for treating over 30 chronic diseases is developed.
|
|
| Locked | Locked | Locked |
Materials management solutions are provided for healthcare organizations.
|
|
| Locked | Locked | Locked |
Wide range of medical devices
|
|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Healthcare solutions are provided by Johnson & Johnson globally.
|
|
| Locked | Locked | Locked |
Diagnostic and surgical products for women's healthcare are provided.
|
Detailed competitors of PAVmed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pavmed
Complete news archive for PAVmed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PAVmed
PAVmed was founded in 2014.
PAVmed is headquartered in New York, United States. It is registered at New York, New York, United States.
PAVmed is a funded company, having raised a total of $845K across 13 funding rounds to date.
As of Dec 31, 2024, the latest employee count at PAVmed is 39.
Annual revenue of PAVmed is $3M as on Dec 31, 2024.
Developer of medical devices and biomarkers to detect various diseases. The products developed by the company include CarpX a minimally invasive device to treat carpal tunnel syndrome, PortIO a novel, implantable, intraosseous vascular access device, and DisappEAR antimicrobial resorbable ear tubes, and many more.
PAVmed's top competitors include Guardant Health, GRAIL and GE Healthcare.
PAVmed offers Lucid Diagnostics and Veris Health.
Yes, PAVmed is publicly traded on NASDAQ under the ticker symbol PAVM.
PAVmed has 1 investor. Key investors include HHS.
The ticker symbol of PAVmed is PAVM on NASDAQ.